217 related articles for article (PubMed ID: 11563995)
1. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole.
Andersson T; Röhss K; Bredberg E; Hassan-Alin M
Aliment Pharmacol Ther; 2001 Oct; 15(10):1563-9. PubMed ID: 11563995
[TBL] [Abstract][Full Text] [Related]
2. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.
Hunt RH; Armstrong D; Yaghoobi M; James C; Chen Y; Leonard J; Shin JM; Lee E; Tang-Liu D; Sachs G
Aliment Pharmacol Ther; 2008 Jul; 28(2):187-99. PubMed ID: 18445141
[TBL] [Abstract][Full Text] [Related]
3. Review article: Esomeprazole--enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion.
Lindberg P; Keeling D; Fryklund J; Andersson T; Lundborg P; Carlsson E
Aliment Pharmacol Ther; 2003 Feb; 17(4):481-8. PubMed ID: 12622756
[TBL] [Abstract][Full Text] [Related]
4. Suppression of gastric acid with intravenous esomeprazole and omeprazole: results of 3 studies in healthy subjects.
Röhss K; Wilder-Smith C; Kilhamn J; Fjellman M; Lind T
Int J Clin Pharmacol Ther; 2007 Jun; 45(6):345-54. PubMed ID: 17595892
[TBL] [Abstract][Full Text] [Related]
5. Review article: pharmacology of esomeprazole and comparisons with omeprazole.
Dent J
Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():5-9. PubMed ID: 12614299
[TBL] [Abstract][Full Text] [Related]
6. A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects.
Hassan-Alin M; Andersson T; Niazi M; Röhss K
Eur J Clin Pharmacol; 2005 Jan; 60(11):779-84. PubMed ID: 15578172
[TBL] [Abstract][Full Text] [Related]
7. [Omeprazol and ezomeprazol pharmacokinetics, duration of antisecretory effect, and reasons for their probable changes in duodenal ulcer].
Serebrova SIu; Starodubtsev AK; Pisarev VV; Kondratenko SN; Vasilenko GF; Dobrovol'skiĭ OV
Eksp Klin Gastroenterol; 2009; (4):86-92. PubMed ID: 19960999
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor.
Tonini M; Vigneri S; Savarino V; Scarpignato C
Dig Liver Dis; 2001 Oct; 33(7):600-6. PubMed ID: 11816552
[TBL] [Abstract][Full Text] [Related]
9. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
[TBL] [Abstract][Full Text] [Related]
10. Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies.
Wilder-Smith CH; Bondarov P; Lundgren M; Niazi M; Röhss K; Ahlbom H; Nyman L
Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):191-7. PubMed ID: 15674097
[TBL] [Abstract][Full Text] [Related]
11. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH.
Junghard O; Hassan-Alin M; Hasselgren G
Eur J Clin Pharmacol; 2002 Oct; 58(7):453-8. PubMed ID: 12389067
[TBL] [Abstract][Full Text] [Related]
12. Intravenous omeprazole in children: pharmacokinetics and effect on 24-hour intragastric pH.
Faure C; Michaud L; Shaghaghi EK; Popon M; Turck D; Navarro J; Jacqz-Aigrain E
J Pediatr Gastroenterol Nutr; 2001 Aug; 33(2):144-8. PubMed ID: 11568514
[TBL] [Abstract][Full Text] [Related]
13. Esomeprazole, a new proton pump inhibitor: pharmacological characteristics and clinical efficacy.
Thitiphuree S; Talley NJ
Int J Clin Pract; 2000 Oct; 54(8):537-41. PubMed ID: 11198734
[TBL] [Abstract][Full Text] [Related]
14. Initial potency of lansoprazole and omeprazole tablets on pentagastrin-stimulated gastric acid secretion-a placebo-controlled study in healthy volunteers.
Müller P; Göksu MA; Fuchs W; Schlüter F; Simon B
Aliment Pharmacol Ther; 2000 Sep; 14(9):1225-9. PubMed ID: 10971240
[TBL] [Abstract][Full Text] [Related]
15. Esomeprazole magnesium (Nexium).
Baker DE
Rev Gastroenterol Disord; 2001; 1(1):32-41. PubMed ID: 12120118
[TBL] [Abstract][Full Text] [Related]
16. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
[TBL] [Abstract][Full Text] [Related]
17. Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease.
Lind T; Rydberg L; Kylebäck A; Jonsson A; Andersson T; Hasselgren G; Holmberg J; Röhss K
Aliment Pharmacol Ther; 2000 Jul; 14(7):861-7. PubMed ID: 10886041
[TBL] [Abstract][Full Text] [Related]
18. Effect of omeprazole paste on gastric acid secretion in horses.
Daurio CP; Holste JE; Andrews FM; Merritt AM; Blackford JT; Dolz F; Thompson DR
Equine Vet J Suppl; 1999 Apr; (29):59-62. PubMed ID: 10696296
[TBL] [Abstract][Full Text] [Related]
19. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
Andersson T; Holmberg J; Röhss K; Walan A
Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
